Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to Sell at Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other research analysts have also recently commented on the company. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Leede Financial raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald raised their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $15.50.

Eupraxia Pharmaceuticals Trading Up 4.7%

Shares of EPRX stock opened at $8.50 on Friday. Eupraxia Pharmaceuticals has a 12 month low of $2.68 and a 12 month high of $9.32. The company has a market capitalization of $305.66 million, a P/E ratio of -9.77 and a beta of 1.20. The stock has a 50 day moving average of $8.02 and a two-hundred day moving average of $6.54.

Institutional Trading of Eupraxia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in EPRX. Vivo Capital LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the third quarter worth approximately $7,965,000. Ally Bridge Group NY LLC bought a new stake in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $5,398,000. Ikarian Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $4,606,000. Squadron Capital Management LLC acquired a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at $3,775,000. Finally, Velan Capital Investment Management LP bought a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at $2,077,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.